Navigation Links
Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
Date:8/11/2009

SEATTLE, Aug. 11 /PRNewswire/ -- Omeros Corporation today announced results from the Phase 1/Phase 2 clinical trial of OMS302, the Company's ophthalmologic PharmacoSurgery(TM) product candidate. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis), each with well-known safety and pharmacologic profiles.

Omeros' Phase 1/Phase 2 trial enrolled 61 patients undergoing age-related cataract extraction with lens replacement, and was designed to evaluate efficacy and safety of Omeros' product candidate added to a standard surgical irrigation solution. The data from this study showed that patients treated with OMS302 reported less postoperative pain and demonstrated statistically significant improvement in maintenance of mydriasis during the surgical procedure compared to patients treated with vehicle control. There were no serious adverse events and no discontinuations due to adverse events.

This Phase 1/Phase 2 clinical trial was a parallel-group, double-blind, vehicle-controlled study evaluating the effects of OMS302 on dilation of the pupil during cataract surgery and on pain, discomfort and inflammation following the procedure. The trial included three arms of equal size. In the first arm, OMS302 including both the mydriatic and anti-inflammatory agents was added to a standard irrigation solution used in ophthalmologic surgery and delivered directly to the eye during the operation. In the second arm, patients received irrigation solution including only the mydriatic agent, and in the third arm, patients received standard irrigation solution only. For efficacy assessments, patients were monitored for pupil size during surgery and for pain and inflammation for 14 days following surgery.

"We are pleased with the results of this study, which suggest that OMS302 would be useful in helping maintain mydriasis throughout cataract surgery a
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... including DESY scientists has observed tiny quantum vortices in ... the journal Science that the exotic vortices ... It is the first time that the quantum vortices, ... what is known as superfluid helium, have been detected ... says Andrey Vilesov of the University of Southern California, ...
(Date:8/21/2014)... August 21, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... therapy, is a means of replacing hormones ... the body. This type of therapy is ...
(Date:8/21/2014)... 21, 2014 Telomere Biosciences, LLC (Telomere ... "TELO-20 for Dogs" with Telomerase Activation Complex ... the world for dogs. Telomeres are the protective ... the body. A wealth of ground-breaking research by ... Science and Aging, including Nobel laureates, has demonstrated ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... Brazil and ... The uptake of several newly approved agents, the ... this indication and the launch of emerging biologics ... markets. In particular, the emerging IL-5 inhibitors will ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... Technologies, Inc., a leading,provider of innovative services ... today that Shabbir Anik, Ph.D.,will join the ... Officer. Dr.,Anik, the former President of Pharmaceutical ... Althea,s expansion of its product development,clinical trial ...
... advanced and powerful electron microscope on the planetcapable of ... for Electron Microscopy at McMaster University. , "We are ... of such a high calibre," says Gianluigi Botton, director ... Materials Science and Engineering, and the project,s leader. ...
... N.C., Oct. 20 With limited information ... support of Continuing,Medical Education activities, pharmaceutical, biotechnology ... understand the value of CME,support and strategies ... practitioner behaviors and patient outcomes. In the ...
Cached Biology Technology:Althea Technologies Appoints Dr. Shabbir Anik as Chief Executive Officer 2McMaster University unveils world's most advanced microscope 2Bio-Pharma Industry Improves Patient Outcomes Through Continuing Medical Education (CME) 2
(Date:8/22/2014)... French . NAIROBI (22 ... soils looming as a major threat to food security across ... the last five years, 1.7 million African farmers in 13 ... hectares and helped them double or even triple crop yields. ... in Africa (AGRA) focuses on intensive efforts initiated five years ...
(Date:8/22/2014)... in basic and clinical research and technological advances, ... complex offensive spanning multiple fronts. , Work happening ... help find new and more selective therapies for ... a specific enzyme overexpressed in certain cancersand they ... tumours. , Chemistry professor Christopher Cairo and his ...
(Date:8/22/2014)... is a multifunctional enzyme that localizes ... neuroprotective and cholesterol-synthesizing activities. DHCR24 overexpression ... amyloid β deposition. Dr. Xiuli Lu ... China constructed two recombinant adenoviruses (Ad-rSYN1-DHCR24-myc ... specifically in neuronal cells. They also ...
Breaking Biology News(10 mins):Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... paleoclimate history by NASA,s Goddard Institute for Space Studies ... climate changes this century, including multiple meters of sea ... By looking at how the Earth,s climate responded to ... question raised by ongoing human-caused climate change: "What is ...
... Mellon University,s Roberto R. Gil and Rongchao Jin ... of infinitesimal gold nanoparticles, which could advance the ... drug development. Their approach offers a ... nanoparticles because it can determine whether the nanoparticles ...
... New York, NYDecember 7, 2011Thanks to a new ... be able to diagnose in their offices non-periodic ... Non-periodic arrhythmias include atrial and ventricular fibrillation, which ... can in some cases be life-threatening. ...
Cached Biology News:Paleoclimate record points toward potential rapid climate changes 2Paleoclimate record points toward potential rapid climate changes 3Paleoclimate record points toward potential rapid climate changes 4Carnegie Mellon researchers use NMR to determine whether gold nanoparticles exhibit 'handedness' 2Carnegie Mellon researchers use NMR to determine whether gold nanoparticles exhibit 'handedness' 3New Columbia engineering technique diagnoses non-periodic arrhythmias in a single heartbeat 2
... Mung Bean Nuclease catalyzes the degradation ... yield 5-phosphoryl terminated products. While the nuclease ... very high concentrations the enzyme degrades double-stranded ... Nuclease has been used for transcript mapping ...
... The S.c. EasyComp Transformation Kit is ... Saccharomyces cerevisiae cells. Advantages over commonly ... formation or LiCl methods include:- Cells can ... 30 minutes - Competent cell preparation and ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
...
Biology Products: